While the FDA has been in the news for a handful of approvals over the past year-plus, New York dermatologist Bruce Katz, MD, and his colleagues, are “beyond excited” for the administration’s upcoming consent in the field of aesthetics.

Enter DAXI, a neuromodulator that Dr. Katz explains is “like Botox, except it lasts longer, with a time span averaging around 24 weeks.”

Read the full article at www.newbeauty.com